Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 100,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $35.80, for a total transaction of $3,580,000.00. Following the transaction, the insider owned 22,802,482 shares in the company, valued at approximately $816,328,855.60. The trade was a 0.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Private Ltd Gic also recently made the following trade(s):
- On Thursday, August 13th, Private Ltd Gic sold 1,500,000 shares of Medline stock. The stock was sold at an average price of $35.80, for a total value of $53,700,000.00.
- On Friday, August 7th, Private Ltd Gic sold 590,284 shares of Medline stock. The stock was sold at an average price of $35.58, for a total value of $21,002,304.72.
- On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02.
- On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80.
Medline Stock Down 2.4%
Shares of NASDAQ MDLN opened at $34.88 on Tuesday. Medline has a 52 week low of $32.81 and a 52 week high of $50.88. The stock's fifty day moving average is $38.32 and its 200 day moving average is $41.28. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. The stock has a market capitalization of $45.86 billion and a P/E ratio of 44.15.
Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion for the quarter. Sell-side analysts forecast that Medline will post 1.51 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on MDLN. Wells Fargo & Company lowered their price objective on shares of Medline from $45.00 to $34.00 and set an "equal weight" rating for the company in a research report on Tuesday, August 11th. JPMorgan Chase & Co. dropped their target price on Medline from $53.00 to $46.00 and set an "overweight" rating for the company in a research report on Wednesday, August 12th. BTIG Research reiterated a "buy" rating and issued a $55.00 price objective on shares of Medline in a report on Friday, July 31st. Royal Bank Of Canada decreased their price target on shares of Medline from $53.00 to $46.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $42.00 price objective on shares of Medline in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $47.42.
Read Our Latest Analysis on MDLN
Institutional Trading of Medline
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mass General Brigham Inc acquired a new position in Medline during the 4th quarter worth approximately $1,104,000. WPG Advisers LLC bought a new stake in shares of Medline during the fourth quarter valued at approximately $38,000. Nadler Financial Group Inc. acquired a new position in shares of Medline during the fourth quarter worth approximately $354,000. NBC Securities Inc. bought a new position in shares of Medline in the 4th quarter worth $28,000. Finally, Vanguard Group Inc. acquired a new stake in Medline in the 4th quarter valued at $793,278,000.
About Medline
(
Get Free Report)
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
